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Background: Failure to thrive (FTT) is a common problem of children especially in underdeveloped countries. In addition to 
its short-term adverse health effects, it is associated with long-term behavioral and cognitive defects. One of the recommended 
treatment modalities for FTT is using synbiotics. Due to high prevalence of FTT with undefined organic causes and failure of most 
medications on treatment of this type of FTT, we decided to search the effect of synbiotics on these patients. Materials and Methods: 
A randomized, triple-blinded, placebo-controlled trial study was done from 2011 to 2012. A number of 84 patients were randomly 
assigned to intervention and control groups. The synbiotics sachets were administered to study group for 6 months. The growth 
indices were measured at the beginning of the trial after 3 and 6 months, and compared with control. Results: Variance analysis of 
observations showed improvement of growth indices in both groups. The increase in weight was significantly higher in synbiotics 
group than in controls (P < 0.05). The corresponding figure was not significant for height and head circumference (P > 0.05). At the 
beginning of the trial, the mean weights were 10.25 ± 0.20 kg and 10.750 ± 0.160 kg in intervention and control groups, respectively, 
Meanwhile, after 6 months, the mean weights of two groups became 12.280 ± 0.190 and 11.760 ± 0.17 kg in intervention and control 
groups, respectively. This result has confirmed that the effect of synbiotics is significant on weight gain of our patients. Conclusion: 
Our findings support beneficial effects of synbiotics in weight gain of children with FTT.
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One method for improving growth parameters 
of children is administration of synbiotics, that 
is,  prebiotics and probiotics. [7] Prebiotics are 
nondigestible food ingredient usually in the form of 
oligosaccharide (galacto-oligosaccharide and fructo-
oligosaccharide). They are used as food for probiotics, 
and cause their growth.[7] Probiotics are also live, 
useful microorganisms, and when administered with 
sufficient dosage (108-1011 CFU), they colonize the 
gastrointestinal tract, suppress pathogenic bacteria 
and may improve health.[8,9]
There are several types of probiotics including 
Lactobacillus, Bifidobacteria and Sacchaomyces species. 
Lactobacillus rhamnosus (LGG) is the first probiotic 
that has been discovered. It is also the most common 
administered form.[8,9] Several studies on probiotics 
exist for FTT patients. Saran et al. evaluated the effect 
of probiotics (Lactobacillus acidophilus) for FTT children 
in India.[10] They found that probiotics can cause an 
increment of weight and height in relation of placebo. 
INTRODUCTION
The growth indices are a valuable scale for evaluation 
and monitoring of child health. Failure to thrive (FTT) 
is defined as a decrease in growth rate according to the 
reference growth charts.[1-4]
As a common problem in children, FTT is one of the 
major health problems especially in underdeveloped 
and developing countries. It is associated with some 
defects such as weight, height, cognitive functions, and 
behavior.[1] About one-third of FTT patients suffer from 
developmental delay, emotional, and socioeconomic 
problems.[5] FTT children have long-term behavioral 
and cognitive defects because these patients are prone to 
recurrent infections especially in the gastrointestinal and 
respiratory tracts. Thus, FTT can cause a heavy economic 
burden for governments as well as for health system at 
individual and public levels. As the etiology of FTT can 
be determined in only 20% of cases,[6] the treatment of 
most cases is a challenging problem for physicians.[6]
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They also observed lower frequency of diarrhea and fever 
episodes in this group than in controls.[10]
A study on 402 Chinese FTT children aged 3-5 years showed 
that probiotics could result in significant improvement of 
height and weight in these patients.[11] In another 6 months-
study on 120 healthy children showed that children 
treated with fortified formula and LGG had better growth 
indices than those receiving formula without probiotics.[12] 
However, a study conducted in Switzerland among healthy 
term infants showed that the effect of the formula with 
probiotic and prebiotics was comparable with formula 
without them, and no difference was seen in anthropometric 
measures between two groups.[13] Likewise, another study 
did not confirm any significant effect of probiotics on 
weight, height and head circumference of 126 infants aged 
0-6 months.[14]
The purpose of the current study was to assess the effect of 
synbiotics on growth indices of a sample of Iranian children 
with FTT and to compare it with controls. Since this study 
was not done for Iranian children till now, we have decided 
to research about this subject.
MATERIALS AND METHODS
A randomized, triple-blinded, placebo-controlled trial 
study was done from 2011 to 2012 in Shahrekord, Iran. The 
patients, physician, and pharmacy, did not know about 
sachets content. Herbs and Medicine Research Center 
of Shahrekord University that made these sachets, have 
knowledge only about the contents by special coding. 
The eligibility criteria consisted of being FTT defined as 
having either a weight for age of <5th percentile or a weight 
for height of <10th percentile,[4] being aged 12-60 months, 
having a gestational age of >36 weeks and a birth weight 
of >2500 g, without congenital anomalies or the other 
chronic diseases. Those who refused to use synbiotic 
were excluded from the study. They were visited by one 
academic pediatrician to rule out organic diseases. For all 
children, screening was done by complete blood count, 
electrolytes, sedimentation rate, blood urea nitrogen, 
creatinine, urinalysis, and stool examination (for occult 
blood, fat and parasites). All patients had normal laboratory 
data. By using random table numbers, they were randomly 
assigned into two groups of 42 patients receiving synbiotics 
or placebo. Two groups were matched for growth indices 
and age. In each group, measurement of weight, height, and 
head circumference were done by the same nurse under 
standard protocols and by using calibrated instruments. 
Weight was measured with seca counterweight (Australia, 
accuracy 0.1 kg), head circumference, length or height by 
one nonelastic tape measure (somatometer France, accuracy 
0.1 cm) at the beginning of the trial, as well as after 3 and 
6 months. These data were then compared with indices in 
the growth chart of each patient. The responsible physician, 
nurse, parents, and children were not aware of the study 
group.
The patients in the case and control groups received 
synbiotics and starch powder in sachet, respectively. 
Parental consent was given for administration. All sachets 
were same form and color. Synbiotic sachets were made 
in form Lactol tablets. The drug is manufactured under 
license of nature’s only company of USA in India. Each tablet 
contains 100 mg fructo-oligosaccharides and 150 million 
spore Bacillus coagulans.
Placebo sachets contained 1 g starch powder. Both sachets 
(placebo and synbiotics) were made by Herbs and Medicine 
Reseach Center of Shahrekord University as mentioned 
above. Both synbiotics and placebo sachets had special 
codes. The patients visited by responsible physician 
monthly and again received the sachet with the same code. 
With returning the empty box of previous sachets, we were 
certain for patients’ compliance. After finishing the study, 
breaking of codes was done. The average increment of 
weight, height and head circumference in each group was 
calculated and analyzed by SPSS 18 software (SPSS Inc., 
Chicago, Illinois, USA) and with Chi-square, independent 
t-test examination, and observational variance analysis. For 
each of the growth indices, a repeated measure analysis of 
variance was used while three measurements were entered 
as within-subject variables and the group as between-subject 
factor. The multivariate F-test of Greenhouse-Geisser was 
used for within-subject analysis. The interaction factor 
between within-subject variable and group evaluated to 
find if the trend of growth parameter during the study vary 
between two groups or not. Furthermore, the independent 
t-test and Chi-square test were used to compare each 
measurement between two groups. P <0.05 was considered 
as significant.
RESULTS
Totally, 84 FTT children (each group 42 children) were 
admitted to our study, of whom 40 children (47.6%) were 
boys (P > 0.05). All children were from 12 to 54 months old, 
the mean age of children at the beginning of the study, and 
also the mean of their growth parameters at their birth were 
shown in the Table 1. There was no difference between age 
of two groups (P > 0.05), also the growth parameters at birth 
between two groups were not significant (P > 0.05).
The mean of growth indices, including weight, height, and 
head circumference during the study, was calculated at the 
beginning of study and on the 3 and 6 months follow-up, 
which were shown in the Table 2. There was no difference 
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between height and weight of two groups in the beginning. 
Nevertheless, head circumference of the control group was 
significantly higher than the intervention group. However, 
no significant difference after intervention was seen. After 3 
and 6 months, no significant difference of height and weight 
were seen in the control group. Meanwhile, a significant 
increment of weight was seen in the intervention group 
(P < 0.05).
Based on repeated measures analysis of variance, there 
is obvious increasing trend for all growth parameters 
during the study. The increasing trend of height and head 
circumference were statistically equal for both group 
(P > 0.05), as one could see from the Figures 1 and 2. 
However, as shown in the Figure 3, the increasing trend of 
weight was significantly higher in the intervention group 
(P < 0.05).
DISCUSSION
This is a controlled clinical trial, which evaluate the effect of 
synbiotic medications on improvement of growth indices in 
children with FTT that no organic cause detected for them. 
The result of this study showed that ingestion of synbiotics 
with adequate dose (100 mg fructo-oligosaccharides 
and 150 million spore B. coagulans) for 6 months caused 
significant improvement of weight of FTT children, but no 
effect on height and head circumference.
Table 1: Mean of age, height, weight, head 
circumference at the beginning of the study
Parameter Intervention  
(mean ± SD)
Control  
(mean ± SD)
P
Age on arrival 
(months)
30.4±13.4 32.9±11.2 0.350
Birth height (cm) 47.35±2.03 47.38±2.09 0.937
Birth weight (g) 2758.1±430.4 2702.4±425.7 0.553
Birth head 
circumference (cm)
34.58±0.80 34.67±0.53 0.573
SD = Standard deviation
Table 2: The mean of growth indices (height, weight, and 
head circumference) at the beginning, after 3 and 6 months
Parameter Intervention  
(mean ± SD)
Control  
(mean ± SD)
P
Height (cm)
On arrival 87.77±10.13 88.86±7.5 0.580
After 3 months 89.40±9.65 90.42±7.37 0.591
After 6 months 91.40±9.29 92.15±7.03 0.679
P >0.05 >0.05
Weight (g)
On arrival 10523.8±2035.7 10758±1675.5 0.566
After 3 months 11388.1±1926.6 11234.5±1668.9 0.049
After 6 months 12288.3±1916.3 11764±1729.2 0.020
P <0.05 >0.05
Head 
circumference (cm)
On arrival 47.62±1.13 48.05±0.84 0.492
After 3 months 47.83±0.97 48.21±0.71 0.413
After 6 months 48.05±0.82 48.37±0.54 0.351
P >0.05 >0.05
SD = Standard deviation
Figure 1: The mean of height at the beginning, after 3 and 6 months
Figure 2: The mean of head circumference at the beginning, after 3 and 6 months
Figure 3: The mean of weight at the beginning, after 3 and 6 months
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In other parts of the world, few studies were done 
in which oral administration of prebiotic + probiotic 
Lactobacillus acidiphillus to FTT children for 6 months 
causes improvement of weight gain and height.[10,11] He 
et al. resulted significant increase in weight and height of 
children receiving probiotic.[11] In our study, only increment 
of weight occurred but no effect on height and head 
circumference were observed. This study and previous 
works show a significant increase in weight, which may be 
due to stimulation of damaged gastrointestinal mucosa by 
these agents.[10,11] Inattention to many clinical advantages of 
probiotics, several factors including bacterial type, dosage, 
route of administration, and some factors such as age and 
dietary regimen probably are responsible for different effects 
of these drugs. For FTT, the first decreasing factor is weight. 
Decreasing in height, and then head circumference gradually 
will happen through progression of malnutrition. With the 
improvement of FTT, weight is the first factor that will rise 
and then height, and head circumference subsequently will 
increase with time. It should be noted that FTT children 
in our study mostly had not appeared short stature. Since 
there is the benefit of synbiotics on stimulation of mucosal 
immunity and improvement of intestinal absorption as well 
as these effects need sufficient time, this is another reason 
that also shows possibility of height velocity increment needs 
more prolonged use of synbiotic (>6 months).
In the opposite to the mentioned studies, Kerac et al. in 
Malavia reported probiotic administration for children 
with acute FTT, which had no effect on weight and 
height.[15] This situation may be due to the difference in 
statistical community or route and dose of probiotic use. 
In Kerac et al. study, there were some HIV-positive patients 
who had received co-trimoxazole that could decrease 
intestinal probiotic colonization.[15] For the existence of the 
ideal response to probiotics, they must pass from upper 
gastrointestinal tract to a small intestine along with colon in 
appropriate condition. Because of killing of some probiotics 
during this transmission, it seems that 1 bolus dose has 
better therapeutic effect than divided dose that used in 
Kerac et al. study.[15] Kerac et al. administered probiotics milk 
for which dose of ingested probiotics was not precise.[15]
For previous studies, the effect of probiotics on head 
circumference did not show a positive response.[10,11,15] Our 
study confirms the same results. The maximum increase 
of head circumference and brain size after birth is in the 6 
months of the 1st year, which is equal to remaining life. In 
the second half of the 1st year, the rate of increment in head 
circumference reaches 0.5 cm/month. The average age of 
children in our study is 12-60 months children. Thus, we 
must not expect a significant increase in head circumference 
of patients that received probiotics. If the study performs on 
earlier ages, the effect of probiotics on head circumference, 
cognition, performance of the nervous system, also could 
be evaluated.
The kind of probiotic administered also could be effective 
because different kinds of probiotics can have different 
effects on patients with different clinical conditions. Hence, 
different results may also be found in part due to different 
types of probiotics.[16]
Another cause for a positive effect of probiotics on weight 
gain of children can be due to decrease episodes of infections 
including pneumonia and gastroenteritis.[17,18] There are some 
evidences that Lactobacil bacteria and Bifidobacteria interact 
directly with viruses and pathogens in food and water as 
well as toxin-producing microbes.[19] Considerable researches 
have, therefore, been carried out regarding the treatment and 
prevention of diarrhea.[20-24] Some investigations showed that 
L. rhamnosus (Lcr35) can control bacterial, viral and bacterial 
respiratory and gastrointestinal disease significantly. Long-
term ingestion of Lcr35 decreased the incidence of bacterial 
infections.[17] In our study, episodes of acute gastroenteritis 
and febrile illness decreased significantly among children 
that received probiotic (P < 0.05).
One problem with administration of synbiotics is safety of 
these agents. Probiotics are live microorganisms and may 
cause infectious diseases in the young infant and immune 
deficient children. Meanwhile, several investigations 
demonstrated that infection rates with Lactobacillus or 
Bifidobacteria are rare, and ingestion of these bacteria is 
safe.[14,20] All patients entered in our investigation tolerated 
synbiotics well without any adverse effect.
The route of administration of synbiotics can also be 
influenced on results. Synbiotics ingestion in the form of 
medication is more effective than synbiotics supplement 
in milk or yogurt because sufficient and precise dose 
administered with a bolus dose in the form of drug, than 
uncertain dose in the latter form.
More studies with more cases of FTT children are need for 
supporting these results. It is better to do such studies with 
more prolong time to evaluate the effect of synbiotics on 
height and head circumference also.
CONCLUSION
Due to high prevalence of FTT in children and its complications 
on cognitive function and behavior, it seems necessary to 
find the appropriate method for treatment of FTT. It may be 
suggested that synbiotics as adjunct therapy for FTT children 
can improve weight gain and decrease complications through 
considering results of this and some previous studies. Although 
more studies are needed to more clearly determine its effects.
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